Log In
Print this Print this

enoblituzumab (MGA271)

  Manage Alerts
Collapse Summary General Information
Company MacroGenics Inc.
DescriptionHumanized mAb against CD276 (B7-H3) with an optimized Fc region
Molecular Target B7-H3 (CD276)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat patients with B7-H3-expressing solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today